Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
James William Burns, Chief Legal Officer of AGIOS PHARMACEUTICALS, INC. (NASDAQ:AGIO), sold 2,799 shares of common stock on June 24, 2025, at a price of $33.54, for a total transaction value of $93,878. The transaction comes as the stock, currently trading at $33.65, has experienced a 7.86% decline over the past week. According to InvestingPro analysis, the company maintains a strong financial position with more cash than debt and a remarkable current ratio of 18.5.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was to cover the tax withholding obligation in respect of vesting of the reporting person’s performance share units. For deeper insights into insider trading patterns and comprehensive financial analysis, InvestingPro subscribers can access detailed research reports covering over 1,400 US stocks, including AGIO’s complete insider transaction history.
On the same day, Burns also exercised options to acquire 6,000 shares of Agios Pharmaceuticals common stock at a price of $0. These performance share units represent a contingent right to receive one share of the issuer’s common stock. With analyst price targets ranging from $38 to $71, investors seeking detailed valuation metrics and additional ProTips can explore the company’s complete financial profile on InvestingPro.
In other recent news, Agios Pharmaceuticals has been at the forefront of several noteworthy developments. The company is anticipating key clinical trial results for its drug mitapivat, with TD Cowen maintaining a buy rating on Agios, expressing high confidence in its potential to reduce vaso-occlusive crises in sickle cell disease. The firm projects significant sales potential, with a market opportunity that could reach approximately $4 billion. Agios also faces a September 7 PDUFA date for mitapivat in thalassemia, which could bring in around $1 billion in global sales. In a separate development, Agios announced an exclusive agreement with Avanzanite Bioscience to commercialize and distribute PYRUKYND® in Europe, the UK, and Switzerland, expanding its reach in the rare disease market. H.C. Wainwright adjusted Agios’s stock target to $56, down from $61, while maintaining a Buy rating, following this partnership. The firm expressed confidence in the potential FDA approval of Pyrukynd for thalassemia, with European approval anticipated in 2026. Cantor Fitzgerald continues to support Agios with an Overweight rating, highlighting confidence in the company’s sales targets for its thalassemia treatment, with projected sales ranging from $300 million to $500 million. Investors are keeping a close watch on Agios’s progress in both the thalassemia and sickle cell disease treatment landscapes as these developments unfold.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.